Clinical Features of Primary Vitreoretinal Lymphoma: A Single-center Study.

Abstract

Background/Aim:

This study aimed to demonstrate the clinical outcomes of primary vitreoretinal lymphoma (PVRL).

Patients and Methods:

Seventeen patients with PVRL who had been treated at Hokkaido University Hospital were enrolled in this study. They were diagnosed based on their cytology, interleukin-10/-6 ratio, and immunoglobulin heavy chain (IgH) gene rearrangement.

Results:

Diagnostic tests detected cytological malignancy among 14 cases (82.3%), high interleukin-10/-6 ratios among 16 cases (94.1%), and IgH monoclonality in 13 cases (76.5%). Systemic corticosteroids were given to seven (41.2%) patients before their diagnosis of PVRL. Treatments after diagnosis comprised intravitreal methotrexate injection, local radiation, and intravenous chemotherapy for 11, seven, and five cases, respectively. Central nervous system and systemic involvements were observed in nine and one case, respectively, and these complications occurred at 3 to 43 months (mean=16 months) after initial ocular presentation.

Conclusion:

Many of our patients did not receive any systemic intervention, and almost half of patients with PVRL developed central nervous system involvement during their follow-up period.

• Authors: Satoru Kase, Kenichi Namba, Daiju Iwata, Kazuomi Mizuuchi, Takako Ito, Keitaro Hase, Kayo Suzuki, Masahiro Onozawa, Nobuyoshi Kitaichi, Susumu Ishida
• Journal: Cancer diagnosis & prognosis (Cancer Diagn Progn) 2021 May-Jun Vol. 1 Issue 2 Pg. 69-75 ISSN: 2732-7787 [Electronic] Greece
• PMID: 35403133 (Publication Type: Journal Article)
• Copyright: Copyright 2021, International Institute of Anticancer Research.